Mupirocin foam

Drug Profile

Mupirocin foam

Alternative Names: MupiFoam; Topical mupirocin - Foamix

Latest Information Update: 02 May 2013

Price : $50

At a glance

  • Originator Foamix
  • Class Antibacterials; Carboxylic acids; Epoxy compounds; Esters; Nonanoic acids; Pyrans; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Skin and soft tissue infections

Most Recent Events

  • 30 Aug 2005 Mupirocin foam is available for licensing (http://www.foamix.co.il)
  • 30 Aug 2005 Phase-II clinical trials in Skin and soft tissue infections in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top